RE: [Histonet] negative IHC controls
opinion you should always run a negative control with every patient run. For
starters, how do you know
Your blocking solutions have worked?
haven't got endogenous biotin activity (especially in liver biopsies) giving a
haven't got a contaminant?
clinical assurance and governance reasons alone I would have thought that
negative controls are essential.
think the reasons for DAKO selling the two reagents separate is for
commercial reasons only (they can charge more) rather than any fact that people
aren't using them.
UK it is considered "best practice" to use negative controls and not to do so
would be frowned upon by the National External Quality Assurance Scheme (NEQAS)
who monitor the quality of immuno carried out by hospitals in the UK, which
nearly every lab in the UK and many more overseas are signed up
negative controls is poor quality control in my book.
I would like to get a feel for how many out there
are running negative control slides for IHC.
In our lab we do just a handful of antibodies and
initially I had been running a negative control slide with each patient slide.
After much discussion with our pathologists, we decided to omit these
negatives (which were conistently negative) and continue to just run a
positive control with each primary antibody for the run. We use the Dako
autostainer and prediluted primaries. The decision to stop running
negatives also coincided with Dako's decision to sell the negative control
sera separately from the primaries (they used to come packaged
together). Perhaps I assumed that discontinuing to pair these reagents
together meant that few labs were using the negatives.
Anyhow, after having reviewed the last QMPLS
(Canada) survey committee comments, I believe the committe would like a
negative control run with each patient tissue slide in order to evaluate
background (they have used NCCLS guide pages as reference).
Incidentally we weren't a part of the survey due to a
Any help or advice would be
<< Previous Message | Next Message >>